Tanvex BioPharma Past Earnings Performance
Past criteria checks 0/6
Tanvex BioPharma has been growing earnings at an average annual rate of 3.8%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been growing at an average rate of 83.5% per year.
Key information
3.8%
Earnings growth rate
15.2%
EPS growth rate
Biotechs Industry Growth | 12.2% |
Revenue growth rate | 83.5% |
Return on equity | -260.3% |
Net Margin | -3,480.0% |
Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How Tanvex BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 61 | -2,137 | 454 | 1,707 |
30 Sep 23 | 60 | -2,097 | 403 | 1,722 |
30 Jun 23 | 63 | -1,996 | 365 | 1,642 |
31 Mar 23 | 49 | -1,917 | 326 | 1,587 |
31 Dec 22 | 22 | -1,641 | 235 | 1,351 |
30 Sep 22 | 19 | -1,514 | 213 | 1,252 |
30 Jun 22 | 12 | -1,508 | 208 | 1,253 |
31 Mar 22 | 9 | -1,460 | 199 | 1,303 |
31 Dec 21 | 5 | -1,543 | 219 | 1,384 |
30 Sep 21 | 1 | -1,663 | 225 | 1,498 |
30 Jun 21 | 0 | -1,720 | 237 | 1,550 |
31 Mar 21 | 0 | -1,903 | 226 | 1,663 |
31 Dec 20 | 0 | -2,104 | 239 | 1,861 |
30 Sep 20 | 0 | -2,170 | 250 | 1,933 |
30 Jun 20 | 0 | -2,403 | 266 | 2,163 |
31 Mar 20 | 0 | -2,374 | 313 | 2,103 |
31 Dec 19 | 0 | -2,274 | 328 | 2,000 |
30 Sep 19 | 0 | -2,187 | 319 | 1,938 |
30 Jun 19 | 0 | -1,974 | 315 | 1,728 |
31 Mar 19 | 0 | -2,081 | 304 | 1,845 |
31 Dec 18 | 0 | -1,894 | 298 | 1,653 |
30 Sep 18 | 0 | -1,850 | 329 | 1,533 |
30 Jun 18 | 0 | -1,681 | 335 | 1,351 |
31 Mar 18 | 0 | -1,389 | 328 | 1,057 |
31 Dec 17 | 0 | -1,410 | 319 | 1,084 |
30 Sep 17 | 0 | -1,469 | 309 | 1,184 |
30 Jun 17 | 0 | -1,462 | 282 | 1,214 |
31 Mar 17 | 0 | -1,432 | 269 | 1,176 |
31 Dec 16 | 0 | -1,244 | 244 | 1,108 |
30 Sep 16 | 0 | -1,027 | 216 | 909 |
30 Jun 16 | 0 | -977 | 205 | 856 |
31 Mar 16 | 0 | -828 | 179 | 746 |
31 Dec 15 | 0 | -835 | 170 | 662 |
30 Sep 15 | 0 | -619 | 154 | 563 |
30 Jun 15 | 0 | -402 | 147 | 455 |
31 Mar 15 | 0 | -333 | 136 | 398 |
31 Dec 14 | 0 | -265 | 124 | 341 |
Quality Earnings: 6541 is currently unprofitable.
Growing Profit Margin: 6541 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6541 is unprofitable, but has reduced losses over the past 5 years at a rate of 3.8% per year.
Accelerating Growth: Unable to compare 6541's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6541 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).
Return on Equity
High ROE: 6541 has a negative Return on Equity (-260.27%), as it is currently unprofitable.